Jordan Goldstein

All Publications

• Anatomic Genetic Heterogeneity Is Uncovered By Concurrent Cell-Free DNA and Tissue Profiling and Predicts Treatment Resistance in Diffuse Large B-Cell Lymphoma Goldstein, J. S., Scherer, F., Sworder, B. J., Diehn, M., Kurtz, D., Alizadeh, A. A. ELSEVIER. 2024: 4357-4358

  View details for DOI 10.1182/blood-2024-209735

  View details for Web of Science ID 001412802400042

• The Clinical Impact and Cost-Effectiveness of PET-Based and Ctdna-Based Evaluation at End-of-Therapy after Frontline Treatment of DLBCL Kambhampati, S., Goldstein, J. S., Buller, S., Roschewski, M., Alizadeh, A. A., Thiruvengadam, N. ELSEVIER. 2024: 2276-2277

  View details for DOI 10.1182/blood-2024-203873

  View details for Web of Science ID 001412639100005

• Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling Rossi, C., Boegeholz, J., Goldstein, J. S., Shi, S., Su, S., Tessoulin, B., Alig, S. K., Garofalo, A., Esfahani, M., Schroers-Martin, J. G., Liu, C., Olsen, M., Kang, X., Tian, F., Kurtz, D., Sugio, T., Noordenbos, T., Andre, M., Fornecker, L., Julia, E., Traverse-Glehen, A., Casasnovas, O., Binkley, M. S., Diehn, M., Ghesquieres, H., Alizadeh, A. A. ELSEVIER. 2024: 853-854

  View details for DOI 10.1182/blood-2024-201644

  View details for Web of Science ID 001412608600046

• ViPOR's Venom - Rationally Targeting DLBCL with Precision. The New England journal of medicine Goldstein, J. S., Alizadeh, A. A. 2024; 390 (23): 2209-2211

  View details for DOI 10.1056/NEJMe2405437

  View details for PubMedID 38899699

• Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC) Isbell, J. M., Goldstein, J., Hamilton, E. G., Liu, S., Eichholz, J., Buonocore, D. J., Rusch, V. W., Bott, M., Molena, D., Rocco, G., Yang, S., Rudin, C. M., Jones, D. R., Roff, A., Schultz, A., Chabon, J. J., Kurtz, D., Alizadeh, A. A., Li, B. T., Diehn, M. LIPPINCOTT WILLIAMS & WILKINS. 2024

  View details for Web of Science ID 001275557401867

• Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy Goldstein, J., Kim, W., Yoon, S., Kim, S., Roschewski, M., Westin, J., Lynch, R. C., Alig, S. K., Close, S., Chabon, J. J., Rossi, D., Wilson, W. H., Diehn, M., Alizadeh, A. A., Kurtz, D. M. AMER SOC HEMATOLOGY. 2023

  View details for DOI 10.1182/blood-2023-187759

  View details for Web of Science ID 001159306700188

• Novel agents in relapsed/refractory diffuse large B-cell lymphoma. Hematological oncology Varma, G., Goldstein, J., Advani, R. H. 2023; 41 Suppl 1: 92-106

  Abstract

  Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), ineligible for or relapsing after autologous stem-cell transplant or chimeric antigen-receptor T-cell therapies have poor outcomes. Several novel agents, polatuzumab vedotin, tafasitamab, loncastuximab tesirine, and selinexor, have been approved and offer new opportunities for this difficult to treat population. Studies are evaluating combination of these agents with chemotherapy and other emerging therapies. Additionally, advances in our understanding of DLBCL biology, genetics, and immune microenvironment have allowed for the identification of new therapeutic targets like Ikaros and Aiolos, IRAK4, MALT1, and CD47 with several agents in ongoing clinical trials. In this chapter we review updated data supporting the use of the approved agents and discuss other emerging novel therapies for patients with R/R DLBCL.

  View details for DOI 10.1002/hon.3143

  View details for PubMedID 37294966